Richard A. F. Dixon, PhD
Texas Heart Institute Positions
- Director Emeritus, Molecular Cardiology Research Laboratory
Interests
- The James T. Willerson Center for Cardiovascular Modeling and Simulation
- pharmacology
- molecular biology
- stem cells
- Non-invasive diagnostic imaging technologies
Education
-
Postgraduate:
Baylor College of Medicine
-
Fellowships:
Johns Hopkins Medical School
Honors, Awards and Memberships
Publications
4862227
WGZKEVDQ
1
alternatives-to-animal-experimentation
10
date
desc
Dixon
5008
https://www.texasheart.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22UQ5DXLDA%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chen%20et%20al.%22%2C%22parsedDate%22%3A%222023-02-16%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BChen%2C%20X.%2C%20Yu%2C%20W.%2C%20Zhang%2C%20J.%20et%20al.%20%282023%29.%20Therapeutic%20angiogenesis%20and%20tissue%20revascularization%20in%20ischemic%20vascular%20disease.%20%26lt%3Bi%26gt%3BJ%20Biol%20Eng%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B17%26lt%3B%5C%2Fi%26gt%3B%2C%2013.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13036-023-00330-2%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13036-023-00330-2%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Therapeutic%20angiogenesis%20and%20tissue%20revascularization%20in%20ischemic%20vascular%20disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xinyue%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wenlu%22%2C%22lastName%22%3A%22Yu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jing%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xiao%22%2C%22lastName%22%3A%22Fan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xiao%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qi%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Su%22%2C%22lastName%22%3A%22Pan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20A.%20F.%22%2C%22lastName%22%3A%22Dixon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pengyang%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peng%22%2C%22lastName%22%3A%22Yu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ao%22%2C%22lastName%22%3A%22Shi%22%7D%5D%2C%22abstractNote%22%3A%22Ischemic%20vascular%20disease%20is%20a%20major%20healthcare%20problem.%20The%20keys%20to%20treatment%20lie%20in%20vascular%20regeneration%20and%20restoration%20of%20perfusion.%20However%2C%20current%20treatments%20cannot%20satisfy%20the%20need%20for%20vascular%20regeneration%20to%20restore%20blood%20circulation.%20As%20biomedical%20research%20has%20evolved%20rapidly%2C%20a%20variety%20of%20potential%20alternative%20therapeutics%20has%20been%20explored%20widely%2C%20such%20as%5Cu00a0growth%20factor-based%20therapy%2C%20cell-based%20therapy%2C%20and%20material-based%20therapy%20including%20nanomedicine%20and%20biomaterials.%20This%20review%20will%20comprehensively%20describe%20the%20main%20pathogenesis%20of%20vascular%20injury%20in%20ischemic%20vascular%20disease%2C%20the%20therapeutic%20function%20of%20the%20above%20three%20treatment%20strategies%2C%20the%20corresponding%20potential%20challenges%2C%20and%20future%20research%20directions.%22%2C%22date%22%3A%22Feb%2016%2C%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs13036-023-00330-2%22%2C%22ISSN%22%3A%221754-1611%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22WGZKEVDQ%22%2C%22LV239TYN%22%2C%22CH4JXISP%22%2C%22JD5ZU4IS%22%5D%2C%22dateModified%22%3A%222023-03-14T14%3A36%3A27Z%22%7D%7D%2C%7B%22key%22%3A%226YCSUJN8%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Liu%20et%20al.%22%2C%22parsedDate%22%3A%222023-02-08%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLiu%2C%20Q.%2C%20Pan%2C%20S.%2C%20Li%2C%20P.%20et%20al.%20%282023%29.%20Hippo%20pathway%20inhibition%20promotes%20metabolic%20adaptability%20and%20antioxidant%20response%20in%20myoblasts.%20%26lt%3Bi%26gt%3BSci%20Rep%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B13%26lt%3B%5C%2Fi%26gt%3B%2C%202232.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-023-29372-8%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-023-29372-8%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Hippo%20pathway%20inhibition%20promotes%20metabolic%20adaptability%20and%20antioxidant%20response%20in%20myoblasts%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qi%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Su%22%2C%22lastName%22%3A%22Pan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pengyang%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20A.%20F.%22%2C%22lastName%22%3A%22Dixon%22%7D%5D%2C%22abstractNote%22%3A%22Metabolic%20plasticity%20in%20a%20hostile%20environment%20ensures%20cell%20survival.%20We%20investigated%20whether%20Hippo%20pathway%20inhibition%20contributed%20to%20cell%20adaptations%20under%20challenging%20conditions.%20We%20examined%20metabolic%20profiles%20and%20fuel%20substrate%20choices%20and%20preferences%20in%20C2C12%20myoblasts%20after%20Hippo%20pathway%20inhibition%20via%20Salvador%20knockdown%20%28SAV1%20KD%29.%20SAV1%20KD%20induced%20higher%20ATP%20production%20and%20a%20more%20energetic%20phenotype.%20Bioenergetic%20profiling%20showed%20enhanced%20key%20mitochondrial%20parameters%20including%20spare%20respiratory%20capacity.%20SAV1%20KD%20cells%20showed%20markedly%20elevated%20glycolysis%20and%20glycolytic%20reserves%3B%20blocking%20other%20fuel-oxidation%20pathways%20enhanced%20mitochondrial%20flexibility%20of%20glucose%20oxidation.%20Under%20limited%20glucose%2C%20endogenous%20fatty%20acid%20oxidation%20increased%20to%20cope%20with%20bioenergetic%20stress.%20Gene%20expression%20patterns%20after%20SAV1%20KD%20suggested%20transcriptional%20upregulation%20of%20key%20metabolic%20network%20regulators%20to%20promote%20energy%20production%20and%20free%20radical%20scavenging%20that%20may%20prevent%20impaired%20lipid%20and%20glucose%20metabolism.%20In%20SAV1%20KD%20cells%2C%20sirtuin%20signaling%20was%20the%20top%20enriched%20canonical%20pathway%20linked%20with%20enhanced%20mitochondrial%20ATP%20production.%20Collectively%2C%20we%20demonstrated%20that%20Hippo%20pathway%20inhibition%20in%20SAV1%20KD%20cells%20induces%20multiple%20metabolic%20properties%2C%20including%20enhancing%20mitochondrial%20spare%20respiratory%20capacity%20or%20glycolytic%20reserve%20to%20cope%20with%20stress%20and%20upregulating%20metabolic%20pathways%20supporting%20elevated%20ATP%20demand%2C%20bioenergetics%2C%20and%20glycolysis%20and%20counteracting%20oxidative%20stress.%20In%20response%20to%20metabolic%20challenges%2C%20SAV1%20KD%20cells%20can%20increase%20fatty%20acid%20oxidation%20or%20glucose-coupled%20oxidative%20phosphorylation%20capacity%20to%20compensate%20for%20substrate%20limitations%20or%20alternative%20fuel%20oxidation%20pathway%20inhibition.%22%2C%22date%22%3A%22Feb%208%2C%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41598-023-29372-8%22%2C%22ISSN%22%3A%222045-2322%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22WGZKEVDQ%22%2C%22LV239TYN%22%2C%22CH4JXISP%22%2C%22JD5ZU4IS%22%5D%2C%22dateModified%22%3A%222023-03-14T14%3A34%3A53Z%22%7D%7D%2C%7B%22key%22%3A%22W3T5H5J2%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mendiola%20et%20al.%22%2C%22parsedDate%22%3A%222022-11-17%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMendiola%2C%20E.%20A.%2C%20Neelakantan%2C%20S.%2C%20Xiang%2C%20Q.%20et%20al.%20%282022%29.%20Contractile%20adaptation%20of%20the%20left%20ventricle%20post-myocardial%20infarction%3A%20predictions%20by%20rodent-specific%20computational%20modeling.%20%26lt%3Bi%26gt%3BAnn%20Biomed%20Eng%26lt%3B%5C%2Fi%26gt%3B.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10439-022-03102-z%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10439-022-03102-z%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Contractile%20adaptation%20of%20the%20left%20ventricle%20post-myocardial%20infarction%3A%20predictions%20by%20rodent-specific%20computational%20modeling%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilio%20A.%22%2C%22lastName%22%3A%22Mendiola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sunder%22%2C%22lastName%22%3A%22Neelakantan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qian%22%2C%22lastName%22%3A%22Xiang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samer%22%2C%22lastName%22%3A%22Merchant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ke%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edward%20W.%22%2C%22lastName%22%3A%22Hsu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20A.%20F.%22%2C%22lastName%22%3A%22Dixon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Vanderslice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reza%22%2C%22lastName%22%3A%22Avazmohammadi%22%7D%5D%2C%22abstractNote%22%3A%22Myocardial%20infarction%20%28MI%29%20results%20in%20cardiac%20myocyte%20death%20and%20the%20formation%20of%20a%20fibrotic%20scar%20in%20the%20left%20ventricular%20free%20wall%20%28LVFW%29.%20Following%20an%20acute%20MI%2C%20LVFW%20remodeling%20takes%20place%20consisting%20of%20several%20alterations%20in%20the%20structure%20and%20properties%20of%20cellular%20and%20extracellular%20components%20with%20a%20heterogeneous%20pattern%20across%20the%20LVFW.%20The%20normal%20function%20of%20the%20heart%20is%20strongly%20influenced%20by%20the%20passive%20and%20active%20biomechanical%20behavior%20of%20the%20LVFW%2C%20and%20progressive%20myocardial%20structural%20remodeling%20can%20have%20a%20detrimental%20effect%20on%20both%20diastolic%20and%20systolic%20functions%20of%20the%20LV%20leading%20to%20heart%20failure.%20Despite%20important%20advances%20in%20understanding%20LVFW%20passive%20remodeling%20in%20the%20setting%20of%20MI%2C%20heterogeneous%20remodeling%20in%20the%20LVFW%20active%20properties%20and%20its%20relationship%20to%20organ-level%20LV%20function%20remain%20understudied.%20To%20address%20these%20gaps%2C%20we%20developed%20high-fidelity%20finite-element%20%28FE%29%20rodent%20computational%20cardiac%20models%20%28RCCMs%29%20of%20MI%20using%20extensive%20datasets%20from%20MI%20rat%20hearts%20representing%20the%20heart%20remodeling%20from%20one-week%20%281-wk%29%20to%20four-week%20%284-wk%29%20post-MI%20timepoints.%20The%20rat-specific%20models%20%28n%20%3D%202%20for%20each%20timepoint%29%20integrate%20detailed%20imaging%20data%20of%20the%20heart%20geometry%2C%20myocardial%20fiber%20architecture%2C%20and%20infarct%20zone%20determined%20using%20late%20gadolinium%20enhancement%20prior%20to%20terminal%20measurements.%20The%20computational%20models%20predicted%20a%20significantly%20higher%20level%20of%20active%20tension%20in%20remote%20myocardium%20in%20early%20post-MI%20hearts%20%281-wk%20post-MI%29%20followed%20by%20a%20return%20to%20near%20the%20control%20level%20in%20late-stage%20MI%20%283-%20and%204-wk%20post-MI%29.%20The%20late-stage%20MI%20rats%20showed%20smaller%20myofiber%20ranges%20in%20the%20remote%20region%20and%20in-silico%20experiments%20using%20RCCMs%20suggested%20that%20the%20smaller%20fiber%20helicity%20is%20consistent%20with%20lower%20contractile%20forces%20needed%20to%20meet%20the%20measured%20ejection%20fractions%20in%20late-stage%20MI.%20In%20contrast%2C%20in-silico%20experiments%20predicted%20that%20collagen%20fiber%20transmural%20orientation%20in%20the%20infarct%20region%20has%20little%20influence%20on%20organ-level%20function.%20In%20addition%2C%20our%20MI%20RCCMs%20indicated%20that%20reduced%20and%20potentially%20positive%20circumferential%20strains%20in%20the%20infarct%20region%20at%20end-systole%20can%20be%20used%20to%20infer%20information%20about%20the%20time-varying%20properties%20of%20the%20infarct%20region.%20The%20detailed%20description%20of%20regional%20passive%20and%20active%20remodeling%20patterns%20can%20complement%20and%20enhance%20the%20traditional%20measures%20of%20LV%20anatomy%20and%20function%20that%20often%20lead%20to%20a%20gross%20and%20limited%20assessment%20of%20cardiac%20performance.%20The%20translation%20and%20implementation%20of%20our%20model%20in%20patient-specific%20organ-level%20simulations%20offer%20to%20advance%20the%20investigation%20of%20individualized%20prognosis%20and%20intervention%20for%20MI.%22%2C%22date%22%3A%22Nov%2017%2C%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs10439-022-03102-z%22%2C%22ISSN%22%3A%221573-9686%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22WGZKEVDQ%22%2C%22BBMMGS3D%22%2C%2242FKW3I4%22%2C%229T6HXJUI%22%2C%22TXW6RMW4%22%5D%2C%22dateModified%22%3A%222023-01-06T17%3A13%3A09Z%22%7D%7D%2C%7B%22key%22%3A%22XTWHIWQS%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Li%20et%20al.%22%2C%22parsedDate%22%3A%222022-07-18%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLi%2C%20P.%2C%20Jin%2C%20C.%2C%20Cui%2C%20C.%20et%20al.%20%282022%29.%20Impact%20of%20family%20history%20of%20coronary%20artery%20disease%20on%20clinical%20outcomes%20in%20Takotsubo%20cardiomyopathy.%20%26lt%3Bi%26gt%3BJ%20Investig%20Med%26lt%3B%5C%2Fi%26gt%3B%2C%20jim-2021-002186.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjim-2021-002186%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjim-2021-002186%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20family%20history%20of%20coronary%20artery%20disease%20on%20clinical%20outcomes%20in%20Takotsubo%20cardiomyopathy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pengyang%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chengyue%22%2C%22lastName%22%3A%22Jin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Can%22%2C%22lastName%22%3A%22Cui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peng%22%2C%22lastName%22%3A%22Cai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shamita%20Alisa%22%2C%22lastName%22%3A%22Manohar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ling%22%2C%22lastName%22%3A%22Jin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xin%22%2C%22lastName%22%3A%22Wei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Su%22%2C%22lastName%22%3A%22Pan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20A.%20F.%22%2C%22lastName%22%3A%22Dixon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qi%22%2C%22lastName%22%3A%22Liu%22%7D%5D%2C%22abstractNote%22%3A%22Family%20history%20of%20coronary%20artery%20disease%20%28FHxCAD%29%20is%20a%20critical%20risk%20factor%20for%20CAD%2C%20underscoring%20the%20contribution%20of%20genetic%20factors%20to%20disease%20pathogenesis%20and%20susceptibility.%20Takotsubo%20cardiomyopathy%20%28TCM%29%20simulates%20the%20clinical%20features%20of%20and%20frequently%20coexists%20with%20CAD.%20However%2C%20the%20association%20between%20FHxCAD%20and%20TCM%20is%20unclear.%20Here%2C%20we%20retrospectively%20examined%20the%20impact%20of%20FHxCAD%20on%20in-hospital%20outcomes%20of%20patients%20with%20TCM.%20Using%20the%20National%20Inpatient%20Sample%20database%20%282016-2018%29%2C%20we%20identified%204733%20patients%20admitted%20to%20hospital%20with%20a%20primary%20diagnosis%20of%20TCM.%20We%20compared%20in-hospital%20outcomes%20and%20complications%20between%20TCM%20patients%20with%20%28n%3D646%2C%2013.7%25%29%20and%20without%20FHxCAD%20%28n%3D646%29%20in%20the%20unmatched%20and%20in%20a%20propensity-score%20matched%20cohort%20%281%3A1%20ratio%29.%20TCM%20with%20FHxCAD%20patients%20had%20a%20reduced%20incidence%20of%20cardiogenic%20shock%2C%20acute%20kidney%20injury%20%28AKI%29%2C%20and%20acute%20respiratory%20failure%20%28ARF%29%3B%20lower%20mortality%20rates%3B%20shorter%20length%20of%20stay%20%28LOS%29%3B%20and%20decreased%20total%20charge%20compared%20with%20TCM%20without%20FHxCAD%20patients%20%28p%26lt%3B0.05%29.%20In%20the%20matched%20cohort%2C%20TCM%20with%20FHxCAD%20patients%20%28vs%20TCM%20without%20FHxCAD%20patients%29%20had%20a%20lower%20incidence%20of%20cardiogenic%20shock%20%282.2%25%20vs%206.3%25%2C%20p%26lt%3B0.001%3B%20OR%200.33%2C%2095%25%20CI%200.18%20to%200.61%29%2C%20AKI%20%285.1%25%20vs%208.7%25%2C%20p%3D0.016%3B%20OR%200.57%2C%2095%25%20CI%200.36%20to%200.88%29%2C%20and%20ARF%20%285.7%25%20vs%2012.7%25%2C%20p%26lt%3B0.001%3B%20OR%200.42%2C%2095%25%20CI%200.28%20to%200.63%29%3B%20decreased%20in-hospital%20mortality%20%28%26lt%3B11%25%20vs%203.1%25%2C%20p%3D0.002%3B%20OR%200.2%2C%2095%25%20CI%200.07%20to%200.57%29%3B%20shorter%20LOS%20%282.66%5Cu00b11.96%20days%20vs%203.40%5Cu00b13.05%20days%2C%20p%26lt%3B0.001%29%3B%20and%20a%20reduced%20total%20charge%20%28p%3D0.001%29%2C%20respectively.%20FHxCAD%20was%20associated%20with%20favorable%20outcomes%20in%20both%20unmatched%20and%20propensity-matched%20cohorts.%22%2C%22date%22%3A%22July%2018%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fjim-2021-002186%22%2C%22ISSN%22%3A%221708-8267%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22WGZKEVDQ%22%2C%22LV239TYN%22%2C%22CH4JXISP%22%2C%222RCWVZ4F%22%5D%2C%22dateModified%22%3A%222022-08-02T14%3A40%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22L82S82KQ%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dai%20et%20al.%22%2C%22parsedDate%22%3A%222022-07-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDai%2C%20Q.%2C%20Li%2C%20P.%2C%20Bose%2C%20A.%20et%20al.%20%282022%29.%20Association%20of%20atrial%20fibrillation%20burden%20with%20in-hospital%20outcomes%20in%20patients%20with%20Takotsubo%20cardiomyopathy.%20%26lt%3Bi%26gt%3BAm%20J%20Med%20Sci%26lt%3B%5C%2Fi%26gt%3B%2C%20S0002-9629%2822%2900296%26%23x2013%3B8.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.amjms.2022.06.019%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.amjms.2022.06.019%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Association%20of%20atrial%20fibrillation%20burden%20with%20in-hospital%20outcomes%20in%20patients%20with%20Takotsubo%20cardiomyopathy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qiying%22%2C%22lastName%22%3A%22Dai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pengyang%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abhishek%22%2C%22lastName%22%3A%22Bose%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peng%22%2C%22lastName%22%3A%22Cai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ling%22%2C%22lastName%22%3A%22Jin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Su%22%2C%22lastName%22%3A%22Pan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20A.%20F.%22%2C%22lastName%22%3A%22Dixon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Douglas%22%2C%22lastName%22%3A%22Laidlaw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qi%22%2C%22lastName%22%3A%22Liu%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20effects%20of%20atrial%20fibrillation%20%28AF%29%20and%20its%20burden%20on%20in-hospital%20mortality%20in%20patients%20with%20Takotsubo%20cardiomyopathy%20%28TCM%29%20are%20unclear.%20Here%2C%20we%20examined%20the%20effect%20of%20AF%20and%20paroxysmal%20AF%20on%20in-hospital%20outcomes%20in%20patients%20with%20TCM.%5CnMETHODS%3A%20We%20used%20ICD-10%20codes%20to%20retrospectively%20identify%20patients%20with%20a%20primary%20diagnosis%20of%20TCM%20in%20the%20National%20Inpatient%20Sample%20database%202016-2018.%20We%20compared%20in-hospital%20outcomes%20in%20TCM%20patients%20with%20and%20without%20AF%20before%20and%20after%20propensity%20score%20matching.%20The%20effect%20of%20AF%20burden%20on%20outcomes%20was%20assessed%20in%20patients%20with%20paroxysmal%20AF%20and%20no%20AF.%5CnRESULTS%3A%20Of%20the%204%2C733%20patients%20with%20a%20primary%20diagnosis%20of%20TCM%2C%20650%20%2813.7%25%29%20had%20AF%2C%20and%204%2C083%20%2886.3%25%29%20did%20not.%20Of%20TCM%20patients%20with%20AF%2C%20368%20%2856.6%25%29%20had%20paroxysmal%20AF.%20In-hospital%20mortality%20was%20higher%20in%20patients%20with%20AF%20before%20%283.4%25%20vs%201.2%25%2C%20P%5Cu00a0%26lt%3B%5Cu00a0%200.001%29%20and%20after%20propensity%20matching%20%283.4%25%20vs%201.7%25%2C%20P%5Cu00a0%3D%5Cu00a00.021%29%20but%20did%20not%20differ%20between%20the%20paroxysmal%20AF%20and%20the%20no%20AF%20groups%20%28P%5Cu00a0%3D%5Cu00a00.205%29.%20In%20the%20matched%20cohorts%2C%20both%20AF%20and%20paroxysmal%20AF%20groups%20were%20associated%20with%20a%20higher%20rate%20of%20cardiogenic%20shock%20%28AF%2C%20P%5Cu00a0%26lt%3B%5Cu00a00.001%3B%20paroxysmal%20AF%2C%20P%5Cu00a0%26lt%3B%5Cu00a00.001%29%2C%20ventricular%20arrhythmia%20%28AF%2C%20P%5Cu00a0%3D%5Cu00a00.002%3B%20paroxysmal%20AF%2C%20P%5Cu00a0%3D%5Cu00a00.02%29%2C%20acute%20kidney%20injury%20%28AF%2C%20P%5Cu00a0%3D%5Cu00a00.007%3B%20paroxysmal%20AF%2C%20P%5Cu00a0%3D%5Cu00a00.008%29%2C%20and%20acute%20respiratory%20failure%20%28AF%2C%20P%5Cu00a0%26lt%3B%5Cu00a00.001%3B%20paroxysmal%20AF%2C%20P%5Cu00a0%26lt%3B%5Cu00a00.001%29%20compared%20with%20the%20no%20AF%20group.%5CnCONCLUSIONS%3A%20Although%20AF%20was%20associated%20with%20increased%20in-hospital%20mortality%2C%20paroxysmal%20AF%20did%20not%20affect%20in-hospital%20mortality%2C%20suggesting%20a%20higher%20AF%20burden%20is%20associated%20with%20worse%20clinical%20outcome%20in%20patients%20with%20TCM.%22%2C%22date%22%3A%22Jul%2003%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.amjms.2022.06.019%22%2C%22ISSN%22%3A%221538-2990%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22WGZKEVDQ%22%2C%22LV239TYN%22%2C%22CH4JXISP%22%2C%22FA6KSIY7%22%5D%2C%22dateModified%22%3A%222023-02-14T20%3A18%3A18Z%22%7D%7D%2C%7B%22key%22%3A%22V95W4SUL%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Babaei%20et%20al.%22%2C%22parsedDate%22%3A%222022-03-31%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBabaei%2C%20H.%2C%20Mendiola%2C%20E.%20A.%2C%20Neelakantan%2C%20S.%20et%20al.%20%282022%29.%20A%20machine%20learning%20model%20to%20estimate%20myocardial%20stiffness%20from%20EDPVR.%20%26lt%3Bi%26gt%3BSci%20Rep%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B12%26lt%3B%5C%2Fi%26gt%3B%2C%205433.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-022-09128-6%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-022-09128-6%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20machine%20learning%20model%20to%20estimate%20myocardial%20stiffness%20from%20EDPVR%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hamed%22%2C%22lastName%22%3A%22Babaei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilio%20A.%22%2C%22lastName%22%3A%22Mendiola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sunder%22%2C%22lastName%22%3A%22Neelakantan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qian%22%2C%22lastName%22%3A%22Xiang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%22%2C%22lastName%22%3A%22Vang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20A.%20F.%22%2C%22lastName%22%3A%22Dixon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dipan%20J.%22%2C%22lastName%22%3A%22Shah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Vanderslice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gaurav%22%2C%22lastName%22%3A%22Choudhary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reza%22%2C%22lastName%22%3A%22Avazmohammadi%22%7D%5D%2C%22abstractNote%22%3A%22In-vivo%20estimation%20of%20mechanical%20properties%20of%20the%20myocardium%20is%20essential%20for%20patient-specific%20diagnosis%20and%20prognosis%20of%20cardiac%20disease%20involving%20myocardial%20remodeling%2C%20including%20myocardial%20infarction%20and%20heart%20failure%20with%20preserved%20ejection%20fraction.%20Current%20approaches%20use%20time-consuming%20finite-element%20%28FE%29%20inverse%20methods%20that%20involve%20reconstructing%20and%20meshing%20the%20heart%20geometry%2C%20imposing%20measured%20loading%2C%20and%20conducting%20computationally%20expensive%20iterative%20FE%20simulations.%20In%20this%20paper%2C%20we%20propose%20a%20machine%20learning%20%28ML%29%20model%20that%20feasibly%20and%20accurately%20predicts%20passive%20myocardial%20properties%20directly%20from%20select%20geometric%2C%20architectural%2C%20and%20hemodynamic%20measures%2C%20thus%20bypassing%20exhaustive%20steps%20commonly%20required%20in%20cardiac%20FE%20inverse%20problems.%20Geometric%20and%20fiber-orientation%20features%20were%20chosen%20to%20be%20readily%20obtainable%20from%20standard%20cardiac%20imaging%20protocols.%20The%20end-diastolic%20pressure-volume%20relationship%20%28EDPVR%29%2C%20which%20can%20be%20obtained%20using%20a%20single-point%20pressure-volume%20measurement%2C%20was%20used%20as%20a%20hemodynamic%20%28loading%29%20feature.%20A%20comprehensive%20ML%20training%20dataset%20in%20the%20geometry-architecture-loading%20space%20was%20generated%2C%20including%20a%20wide%20variety%20of%20partially%20synthesized%20rodent%20heart%20geometry%20and%20myofiber%20helicity%20possibilities%2C%20and%20a%20broad%20range%20of%20EDPVRs%20obtained%20using%20forward%20FE%20simulations.%20Latin%20hypercube%20sampling%20was%20used%20to%20create%202500%20examples%20for%20training%2C%20validation%2C%20and%20testing.%20A%20multi-layer%20feed-forward%20neural%20network%20%28MFNN%29%20was%20used%20as%20a%20deep%20learning%20agent%20to%20train%20the%20ML%20model.%20The%20model%20showed%20excellent%20performance%20in%20predicting%20stiffness%20parameters%20%5BFormula%3A%20see%20text%5D%20and%20%5BFormula%3A%20see%20text%5D%20associated%20with%20fiber%20direction%20%28%5BFormula%3A%20see%20text%5D%20and%20%5BFormula%3A%20see%20text%5D%29.%20After%20conducting%20permutation%20feature%20importance%20analysis%2C%20the%20ML%20performance%20further%20improved%20for%20%5BFormula%3A%20see%20text%5D%20%28%5BFormula%3A%20see%20text%5D%29%2C%20and%20the%20left%20ventricular%20volume%20and%20endocardial%20area%20were%20found%20to%20be%20the%20most%20critical%20geometric%20features%20for%20accurate%20predictions.%20The%20ML%20model%20predictions%20were%20evaluated%20further%20in%20two%20cases%3A%20%28i%29%20rat-specific%20stiffness%20data%20measured%20using%20ex-vivo%20mechanical%20testing%2C%20and%20%28ii%29%20patient-specific%20estimation%20using%20FE%20inverse%20modeling.%20Excellent%20agreements%20with%20ML%20predictions%20were%20found%20for%20both%20cases.%20The%20trained%20ML%20model%20offers%20a%20feasible%20technology%20to%20estimate%20patient-specific%20myocardial%20properties%2C%20thus%2C%20bridging%20the%20gap%20between%20EDPVR%2C%20as%20a%20confounded%20organ-level%20metric%20for%20tissue%20stiffness%2C%20and%20intrinsic%20tissue-level%20properties.%20These%20properties%20provide%20incremental%20information%20relative%20to%20traditional%20organ-level%20indices%20for%20cardiac%20function%2C%20improving%20the%20clinical%20assessment%20and%20prognosis%20of%20cardiac%20diseases.%22%2C%22date%22%3A%22Mar%2031%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41598-022-09128-6%22%2C%22ISSN%22%3A%222045-2322%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22WGZKEVDQ%22%2C%22BBMMGS3D%22%2C%229T6HXJUI%22%2C%22ZH6PLEMG%22%5D%2C%22dateModified%22%3A%222022-05-04T15%3A31%3A48Z%22%7D%7D%2C%7B%22key%22%3A%22LJXRLHDP%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Li%20et%20al.%22%2C%22parsedDate%22%3A%222022-03-15%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLi%2C%20P.%2C%20Wang%2C%20Y.%2C%20Liang%2C%20J.%20et%20al.%20%282022%29.%20Takotsubo%20syndrome%20and%20respiratory%20diseases%3A%20A%20systematic%20review%20M.%20B%26%23xE4%3Bck%20%28ed.%29%2C.%20%26lt%3Bi%26gt%3BEuropean%20Heart%20Journal%20Open%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B2%26lt%3B%5C%2Fi%26gt%3B%2C%20oeac009.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fehjopen%5C%2Foeac009%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fehjopen%5C%2Foeac009%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Takotsubo%20syndrome%20and%20respiratory%20diseases%3A%20A%20systematic%20review%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pengyang%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yanxuan%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jing%22%2C%22lastName%22%3A%22Liang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xinyu%22%2C%22lastName%22%3A%22Zuo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qiuyue%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Akil%20Adrian%22%2C%22lastName%22%3A%22Sherif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jingyi%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yidan%22%2C%22lastName%22%3A%22Xu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zirui%22%2C%22lastName%22%3A%22Huang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Man%22%2C%22lastName%22%3A%22Dong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Teng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Su%22%2C%22lastName%22%3A%22Pan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20A%20F%22%2C%22lastName%22%3A%22Dixon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xin%22%2C%22lastName%22%3A%22Wei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lingling%22%2C%22lastName%22%3A%22Wu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chengyue%22%2C%22lastName%22%3A%22Jin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peng%22%2C%22lastName%22%3A%22Cai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qiying%22%2C%22lastName%22%3A%22Dai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jianjun%22%2C%22lastName%22%3A%22Ma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qi%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22editor%22%2C%22firstName%22%3A%22Magnus%22%2C%22lastName%22%3A%22B%5Cu00e4ck%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Takotsubo%20syndrome%20%28TTS%29%20is%20a%20rare%20cardiovascular%20condition%20characterized%20by%20reversible%20ventricular%20dysfunction%20and%20a%20presentation%20resembling%20that%20of%20acute%20myocardial%20infarction.%20An%20increasing%20number%20of%20studies%20has%20shown%20the%20association%20of%20respiratory%20diseases%20with%20TTS.%20Here%2C%20we%20comprehensively%20reviewed%20the%20literature%20and%20examined%20the%20available%20evidence%20for%20this%20association.%20After%20searching%20PubMed%2C%20EMBASE%2C%20and%20Cochrane%20Library%20databases%2C%20two%20investigators%20independently%20reviewed%203117%20studies%20published%20through%20May%202021.%20Of%20these%20studies%2C%2099%20met%20the%20inclusion%20criteria%20%28n%5Cu2009%3D%5Cu2009108%20patients%29.%20In%20patients%20with%20coexisting%20respiratory%20disease%20and%20TTS%2C%20the%20most%20common%20TTS%20symptom%20was%20dyspnoea%20%2870.48%25%29%2C%20followed%20by%20chest%20pain%20%2824.76%25%29%20and%20syncope%20%282.86%25%29.%20The%20most%20common%20type%20of%20TTS%20was%20apical%2C%20accounting%20for%2081.13%25%20of%20cases%2C%20followed%20by%20the%20midventricular%20%288.49%25%29%2C%20basal%20%288.49%25%29%2C%20and%20biventricular%20%281.89%25%29%20types.%20Among%20the%20TTS%20cases%2C%2039.82%25%20were%20associated%20with%20obstructive%20lung%20disease%20and%2038.89%25%20were%20associated%20with%20pneumonia.%20Coronavirus%20disease%202019%20%28COVID-19%29%2C%20which%20has%20been%20increasingly%20reported%20in%20patients%20with%20TTS%2C%20was%20identified%20in%2029%20of%2042%20%2869.05%25%29%20patients%20with%20pneumonia.%20The%20overall%20mortality%20rate%20for%20patients%20admitted%20for%20respiratory%20disease%20complicated%20by%20TTS%20was%2012.50%25.%20Obstructive%20lung%20disease%20and%20pneumonia%20are%20the%20most%20frequently%20identified%20respiratory%20triggers%20of%20TTS.%20Medications%20and%20invasive%20procedures%20utilized%20in%20managing%20respiratory%20diseases%20may%20also%20contribute%20to%20the%20development%20of%20TTS.%20Furthermore%2C%20the%20diagnosis%20of%20TTS%20triggered%20by%20these%20conditions%20can%20be%20challenging%20due%20to%20its%20atypical%20presentation.%20Future%20prospective%20studies%20are%20needed%20to%20establish%20appropriate%20guidelines%20for%20managing%20respiratory%20disease%20with%20concurrent%20TTS.%22%2C%22date%22%3A%22Mar%2015%202022%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Fehjopen%5C%2Foeac009%22%2C%22ISSN%22%3A%222752-4191%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Fehjopen%5C%2Farticle%5C%2Fdoi%5C%2F10.1093%5C%2Fehjopen%5C%2Foeac009%5C%2F6535735%22%2C%22collections%22%3A%5B%22WGZKEVDQ%22%2C%22LV239TYN%22%2C%22CH4JXISP%22%2C%22LNSKD4V3%22%5D%2C%22dateModified%22%3A%222022-03-29T18%3A10%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22VXMX4AQ8%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lu%20et%20al.%22%2C%22parsedDate%22%3A%222021-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLu%2C%20X.%2C%20Li%2C%20P.%2C%20Teng%2C%20C.%20et%20al.%20%282021%29.%20Prognostic%20factors%20of%20Takotsubo%20cardiomyopathy%3A%20a%20systematic%20review.%20%26lt%3Bi%26gt%3BESC%20Heart%20Fail%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B8%26lt%3B%5C%2Fi%26gt%3B%2C%203663%26%23x2013%3B3689.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fehf2.13531%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fehf2.13531%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prognostic%20factors%20of%20Takotsubo%20cardiomyopathy%3A%20a%20systematic%20review%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xiaojia%22%2C%22lastName%22%3A%22Lu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pengyang%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Teng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peng%22%2C%22lastName%22%3A%22Cai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ling%22%2C%22lastName%22%3A%22Jin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chenlin%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qi%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Su%22%2C%22lastName%22%3A%22Pan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20A.%20F.%22%2C%22lastName%22%3A%22Dixon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bin%22%2C%22lastName%22%3A%22Wang%22%7D%5D%2C%22abstractNote%22%3A%22Takotsubo%20cardiomyopathy%20%28TCM%29%2C%20characterized%20by%20reversible%20ventricular%20dysfunction%2C%20has%20similar%20mortality%20to%20acute%20coronary%20syndrome.%20With%20the%20growing%20interest%20in%20the%20diagnosis%20of%20and%20interventions%20for%20TCM%2C%20many%20risk%20factors%20had%20been%20found%20to%20affect%20the%20prognosis%20of%20TCM%20patients%2C%20such%20as%20age%2C%20sex%2C%20and%20pre-existing%20diseases.%20Because%20of%20the%20incomplete%20understanding%20of%20the%20pathophysiologic%20mechanism%20in%20TCM%2C%20evidence-based%20medical%20therapy%20for%20this%20condition%20is%20lacking.%20Early%20intervention%20on%20risk%20factors%20may%20improve%20the%20outcomes%20of%20TCM.%20In%20this%20review%2C%20we%20sought%20to%20provide%20up-to-date%20evidence%20on%20risk%20factors%20and%20medical%20therapies%20that%20affect%20TCM%20outcome.%20We%20found%20that%20male%20sex%2C%20physical%20triggers%2C%20and%20certain%20comorbidities%20such%20as%20chronic%20kidney%20disease%2C%20malignant%20disease%2C%20higher%20body%20mass%20index%2C%20sepsis%2C%20chronic%20obstructive%20pulmonary%20disease%2C%20and%20anaemia%20were%20associated%20with%20poor%20TCM%20prognosis.%20In%20contrast%2C%20race%2C%20hyperlipidaemia%2C%20diabetes%20mellitus%2C%20and%20mood%20disorders%20were%20not%20clearly%20associated%20with%20TCM%20prognosis.%20We%20also%20reviewed%20the%20effect%20of%20medical%20therapies%20on%20TCM%20outcome%2C%20including%20angiotensin-converting%20enzyme%20inhibitors%5C%2Fangiotensin%20receptor%20blockers%2C%20%5Cu03b2-blockers%2C%20calcium%20channel%20blockers%2C%20and%20statins.%20The%20evidence%20that%20these%20medications%20confer%20a%20survival%20benefit%20on%20TCM%20patients%20is%20limited.%20Understanding%20these%20prognostic%20factors%20could%20help%20develop%20risk-stratification%20tools%20for%20TCM%20and%20establish%20effective%20prevention%20and%20interventions%20for%20this%20not-so-benign%20condition.%20Further%20multicentre%20clinical%20studies%20with%20large%20samples%20and%20meta-analyses%20of%20findings%20from%20previous%20studies%20are%20needed%20to%20address%20the%20inconsistent%20findings%20among%20the%20many%20potential%20risk%20factors%20for%20TCM.%22%2C%22date%22%3A%22Oct%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fehf2.13531%22%2C%22ISSN%22%3A%222055-5822%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22WGZKEVDQ%22%2C%22LV239TYN%22%2C%22CH4JXISP%22%5D%2C%22dateModified%22%3A%222021-10-29T18%3A39%3A30Z%22%7D%7D%2C%7B%22key%22%3A%22WI8DLRGC%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Liu%20et%20al.%22%2C%22parsedDate%22%3A%222021-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLiu%2C%20Q.%2C%20Pan%2C%20S.%2C%20Liu%2C%20S.%20et%20al.%20%282021%29.%20Suppressing%20Hippo%20signaling%20in%20the%20stem%20cell%20niche%20promotes%20skeletal%20muscle%20regeneration.%20%26lt%3Bi%26gt%3BStem%20Cells%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B39%26lt%3B%5C%2Fi%26gt%3B%2C%20737%26%23x2013%3B749.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fstem.3343%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fstem.3343%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Suppressing%20Hippo%20signaling%20in%20the%20stem%20cell%20niche%20promotes%20skeletal%20muscle%20regeneration%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qi%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Su%22%2C%22lastName%22%3A%22Pan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shijie%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sui%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20T.%22%2C%22lastName%22%3A%22Willerson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20F.%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20A.%20F.%22%2C%22lastName%22%3A%22Dixon%22%7D%5D%2C%22abstractNote%22%3A%22Lack%20of%20blood%20flow%20to%20the%20lower%20extremities%20in%20peripheral%20arterial%20disease%20causes%20oxygen%20and%20nutrient%20deprivation%20in%20ischemic%20skeletal%20muscles%2C%20leading%20to%20functional%20impairment.%20Treatment%20options%20for%20muscle%20regeneration%20in%20this%20scenario%20are%20lacking.%20Here%2C%20we%20selectively%20targeted%20the%20Hippo%20pathway%20in%20myofibers%2C%20which%20provide%20architectural%20support%20for%20muscle%20stem%20cell%20niches%2C%20to%20facilitate%20functional%20muscle%20recovery%20in%20ischemic%20extremities%20by%20promoting%20angiogenesis%2C%20neovascularization%2C%20and%20myogenesis.%20We%20knocked%20down%20the%20core%20Hippo%20pathway%20component%2C%20Salvador%20%28SAV1%29%2C%20by%20using%20an%20adeno-associated%20virus%209%20%28AAV9%29%20vector%20expressing%20a%20miR30-based%20triple%20short-hairpin%20RNA%20%28shRNA%29%2C%20controlled%20by%20a%20muscle-specific%20promoter.%20In%20a%20mouse%20hindlimb-ischemia%20model%2C%20AAV9%20SAV1%20shRNA%20administration%20in%20ischemic%20muscles%20induced%20nuclear%20localization%20of%20the%20Hippo%20effector%20YAP%2C%20accelerated%20perfusion%20restoration%2C%20and%20increased%20exercise%20endurance.%20Intravascular%20lectin%20labeling%20of%20the%20vasculature%20revealed%20enhanced%20angiogenesis.%20Using%205-ethynyl-2%26%23039%3B-deoxyuridine%20to%20label%20replicating%20cellular%20DNA%20in%20vivo%2C%20we%20found%20SAV1%20knockdown%20concurrently%20increased%20paired%20box%20transcription%20factor%20Pax7%2B%20muscle%20satellite%20cell%20and%20CD31%2B%20endothelial%20cell%20proliferation%20in%20ischemic%20muscles.%20To%20further%20study%20Hippo%20suppression%20in%20skeletal%20muscle%20regeneration%2C%20we%20used%20a%20cardiotoxin-induced%20muscle%20damage%20model%20in%20adult%20%2812-15%5Cu2009weeks%20old%29%20and%20aged%20mice%20%2826-month%20old%29.%20Two%20weeks%20after%20delivery%20of%20AAV9%20SAV1%20shRNA%20into%20injured%20muscles%2C%20the%20distribution%20of%20regenerative%20myofibers%20shifted%20toward%20a%20larger%20cross-sectional%20area%20and%20increased%20capillary%20density%20compared%20with%20mice%20receiving%20AAV9%20control.%20Together%2C%20these%20findings%20suggest%20our%20approach%20may%20have%20clinical%20promise%20in%20regenerative%20therapy%20for%20leg%20ischemia%20and%20muscle%20injury.%22%2C%22date%22%3A%22Jun%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fstem.3343%22%2C%22ISSN%22%3A%221549-4918%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NNUFWYNJ%22%2C%22WGZKEVDQ%22%2C%227IGCL8QC%22%2C%22LV239TYN%22%2C%22WK6JRAQQ%22%2C%22CH4JXISP%22%5D%2C%22dateModified%22%3A%222021-06-08T15%3A37%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22DLF89E6R%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chen%20et%20al.%22%2C%22parsedDate%22%3A%222021-05-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BChen%2C%20D.-Y.%2C%20Sawamura%2C%20T.%2C%20%26lt%3Bstrong%26gt%3BDixon%26lt%3B%5C%2Fstrong%26gt%3B%2C%20R.%20A.%20F.%20et%20al.%20%282021%29.%20Autoimmune%20rheumatic%20diseases%3A%20An%20update%20on%20the%20role%20of%20atherogenic%20electronegative%20LDL%20and%20potential%20therapeutic%20strategies.%20%26lt%3Bi%26gt%3BJ%20Clin%20Med%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B10%26lt%3B%5C%2Fi%26gt%3B.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fjcm10091992%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fjcm10091992%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Autoimmune%20rheumatic%20diseases%3A%20An%20update%20on%20the%20role%20of%20atherogenic%20electronegative%20LDL%20and%20potential%20therapeutic%20strategies%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Der-Yuan%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tatsuya%22%2C%22lastName%22%3A%22Sawamura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20A.%20F.%22%2C%22lastName%22%3A%22Dixon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%20Luis%22%2C%22lastName%22%3A%22S%5Cu00e1nchez-Quesada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chu-Huang%22%2C%22lastName%22%3A%22Chen%22%7D%5D%2C%22abstractNote%22%3A%22Atherosclerosis%20has%20been%20linked%20with%20an%20increased%20risk%20of%20atherosclerotic%20cardiovascular%20disease%20%28ASCVD%29.%20Autoimmune%20rheumatic%20diseases%20%28AIRDs%29%20are%20associated%20with%20accelerated%20atherosclerosis%20and%20ASCVD.%20However%2C%20the%20mechanisms%20underlying%20the%20high%20ASCVD%20burden%20in%20patients%20with%20AIRDs%20cannot%20be%20explained%20only%20by%20conventional%20risk%20factors%20despite%20disease-specific%20factors%20and%20chronic%20inflammation.%20Nevertheless%2C%20the%20normal%20levels%20of%20plasma%20low-density%20lipoprotein%20%28LDL%29%20cholesterol%20observed%20in%20most%20patients%20with%20AIRDs%20do%20not%20exclude%20the%20possibility%20of%20increased%20LDL%20atherogenicity.%20By%20using%20anion-exchange%20chromatography%2C%20human%20LDL%20can%20be%20divided%20into%20five%20increasingly%20electronegative%20subfractions%2C%20L1%20to%20L5%2C%20or%20into%20electropositive%20and%20electronegative%20counterparts%2C%20LDL%20%28%2B%29%20and%20LDL%20%28-%29.%20Electronegative%20L5%20and%20LDL%20%28-%29%20have%20similar%20chemical%20compositions%20and%20can%20induce%20adverse%20inflammatory%20reactions%20in%20vascular%20cells.%20Notably%2C%20the%20percentage%20of%20L5%20or%20LDL%20%28-%29%20in%20total%20LDL%20is%20increased%20in%20normolipidemic%20patients%20with%20AIRDs.%20Electronegative%20L5%20and%20LDL%20%28-%29%20are%20not%20recognized%20by%20the%20normal%20LDL%20receptor%20but%20instead%20signal%20through%20the%20lectin-like%20oxidized%20LDL%20receptor%201%20%28LOX-1%29%20to%20activate%20inflammasomes%20involving%20interleukin%201%5Cu03b2%20%28IL-1%5Cu03b2%29.%20Here%2C%20we%20describe%20the%20detailed%20mechanisms%20of%20AIRD-related%20ASCVD%20mediated%20by%20L5%20or%20LDL%20%28-%29%20and%20discuss%20the%20potential%20targeting%20of%20LOX-1%20or%20IL-1%5Cu03b2%20signaling%20as%20new%20therapeutic%20modalities%20for%20these%20diseases.%22%2C%22date%22%3A%22May%2006%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fjcm10091992%22%2C%22ISSN%22%3A%222077-0383%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22IVWSNHMB%22%2C%22WGZKEVDQ%22%5D%2C%22dateModified%22%3A%222021-06-08T17%3A10%3A32Z%22%7D%7D%5D%7D
Chen, X., Yu, W., Zhang, J. et al. (2023). Therapeutic angiogenesis and tissue revascularization in ischemic vascular disease. J Biol Eng 17, 13. https://doi.org/10.1186/s13036-023-00330-2.
Liu, Q., Pan, S., Li, P. et al. (2023). Hippo pathway inhibition promotes metabolic adaptability and antioxidant response in myoblasts. Sci Rep 13, 2232. https://doi.org/10.1038/s41598-023-29372-8.
Mendiola, E. A., Neelakantan, S., Xiang, Q. et al. (2022). Contractile adaptation of the left ventricle post-myocardial infarction: predictions by rodent-specific computational modeling. Ann Biomed Eng. https://doi.org/10.1007/s10439-022-03102-z.
Li, P., Jin, C., Cui, C. et al. (2022). Impact of family history of coronary artery disease on clinical outcomes in Takotsubo cardiomyopathy. J Investig Med, jim-2021-002186. https://doi.org/10.1136/jim-2021-002186.
Dai, Q., Li, P., Bose, A. et al. (2022). Association of atrial fibrillation burden with in-hospital outcomes in patients with Takotsubo cardiomyopathy. Am J Med Sci, S0002-9629(22)00296–8. https://doi.org/10.1016/j.amjms.2022.06.019.
Babaei, H., Mendiola, E. A., Neelakantan, S. et al. (2022). A machine learning model to estimate myocardial stiffness from EDPVR. Sci Rep 12, 5433. https://doi.org/10.1038/s41598-022-09128-6.
Li, P., Wang, Y., Liang, J. et al. (2022). Takotsubo syndrome and respiratory diseases: A systematic review M. Bäck (ed.),. European Heart Journal Open 2, oeac009. https://doi.org/10.1093/ehjopen/oeac009.
Lu, X., Li, P., Teng, C. et al. (2021). Prognostic factors of Takotsubo cardiomyopathy: a systematic review. ESC Heart Fail 8, 3663–3689. https://doi.org/10.1002/ehf2.13531.
Liu, Q., Pan, S., Liu, S. et al. (2021). Suppressing Hippo signaling in the stem cell niche promotes skeletal muscle regeneration. Stem Cells 39, 737–749. https://doi.org/10.1002/stem.3343.
Chen, D.-Y., Sawamura, T., Dixon, R. A. F. et al. (2021). Autoimmune rheumatic diseases: An update on the role of atherogenic electronegative LDL and potential therapeutic strategies. J Clin Med 10. https://doi.org/10.3390/jcm10091992.
